SecurityATRS / Antares Pharma, Inc. (036642106)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding156,788,986 shares (as of 2017-12-31)
Total Insiders18
Total Directors8
Total Officers6

Stock Insider Trading (from SEC Form 4)

ATRS / Antares Pharma, Inc. Insider Trades

Antares Pharma, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ATRS / Antares Pharma, Inc. insiders include GRAHAM PETER J, Deerfield International Master Fund, L.P. GONELLA JACQUES, SAMSON MARVIN, Powell Fred M, JACOB LEONARD S, Flynn James E, GUETH ANTON, DEERFIELD MANAGEMENT CO, Deerfield Special Situations Fund, L.P., GARRITY THOMAS J, Fickenscher James E, HOBBS EAMONN P, Stacey Jennifer Evans, APPLE ROBERT F, ROCHE ROBERT P JR, DEERFIELD PARTNERS, L.P., and Deerfield Mgmt L.P., .

Insider Roster

Insider Dir Off 10% Shares Owned
GONELLA JACQUES Director
X 11,165,351
APPLE ROBERT F President & CEO, Director
X X 1,304,919
JACOB LEONARD S Director
X 239,892
GARRITY THOMAS J Director
X 160,213
Powell Fred M Senior Vice President & CFO
X 331,434
ROCHE ROBERT P JR Director
X
SAMSON MARVIN Director
X
GUETH ANTON Director
X
GRAHAM PETER J SVP General Counsel, Secretary
X 225,851
Fickenscher James E Senior Vice President & CFO
X
Deerfield Special Situations Fund, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield Mgmt L.P. 10% Owner
Flynn James E 10% Owner
X
HOBBS EAMONN P President & CEO, Director
X X
Deerfield International Master Fund, L.P. 10% Owner
Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
X
Deerfield Mgmt L.P. 10% Owner
Flynn James E 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
X
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield Mgmt L.P. 10% Owner
Flynn James E 10% Owner
Deerfield Special Situations Fund, L.P. 10% Owner
X
Flynn James E 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield Special Situations Fund, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield Mgmt L.P. 10% Owner
X
Stacey Jennifer Evans SVP, General Counsel & Secty
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-18 4 GONELLA JACQUES S D 2.60 -21,062 11,165,351 29,029,913
2018-05-17 4 GONELLA JACQUES S D 2.55 -100,000 11,186,413 28,525,353
2018-05-16 4 GONELLA JACQUES S D 2.52 -100,000 11,286,413 28,441,761
2018-05-15 4 GONELLA JACQUES S D 2.50 -100,000 11,386,413 28,466,032
2018-05-14 4 GONELLA JACQUES S D 2.50 -100,000 11,486,413 28,716,032
2018-05-11 4 GONELLA JACQUES S D 2.47 -100,000 11,586,413 28,618,440
2018-05-10 4 GONELLA JACQUES S D 2.36 -100,000 11,686,413 27,579,935
2018-05-11 4 APPLE ROBERT F F D 2.52 -30,052 1,304,919
2018-05-11 4 APPLE ROBERT F M D 0.85 82,500 1,334,971
2018-05-09 4 GONELLA JACQUES S D 2.4746 -150,000 11,786,413 29,166,658
2018-05-09 4 GONELLA JACQUES S D 2.4614 -150,000 11,936,413 29,380,287
2018-05-03 4 GONELLA JACQUES M D 0.85 30,000 12,086,413
2018-03-29 4 JACOB LEONARD S M D 0.85 32,407 239,892
2018-02-22 4 APPLE ROBERT F F D 2.20 -37,001 1,252,471
2018-02-22 4 APPLE ROBERT F A D 113,835 1,289,472
2017-10-09 4 JACOB LEONARD S S X D 4.0521 -200,000 207,485 840,750
2017-10-09 4 JACOB LEONARD S M X D 0.50 188,600 407,485
2017-10-09 4 JACOB LEONARD S S X D 4.05 -30,000 218,885 886,484
2017-10-09 4 JACOB LEONARD S M X D 0.85 30,000 248,885
2017-10-03 4 GARRITY THOMAS J S X D 3.50 -30,000 160,213 560,746
2017-10-03 4 GARRITY THOMAS J M X D 0.85 30,000 190,213
2017-06-09 4 Powell Fred M P D 2.7944 130,000 331,434 926,159
2017-06-07 4 GRAHAM PETER J A D 2.66 101,434 225,851
2017-06-02 4 GRAHAM PETER J F D 2.57 -16,633 124,417
2017-06-07 4 Powell Fred M A D 2.66 101,434 201,434
2017-06-07 4 APPLE ROBERT F A D 2.66 -338,115 1,175,637
2017-06-02 4 APPLE ROBERT F F D 2.57 -38,034 837,522
2017-05-29 4 APPLE ROBERT F F D 2.51 -3,390 875,556
2017-05-28 4 APPLE ROBERT F F D 2.51 -14,903 878,946
2017-02-22 4 APPLE ROBERT F F D 2.37 -1,763 893,849
2017-02-22 4 APPLE ROBERT F A D 5,612 895,612
2017-04-10 4 SAMSON MARVIN G D 2.80 -50,000 52,778
2017-04-05 4 APPLE ROBERT F S X D 3.00 -3,000 890,002 2,670,006
2017-04-05 4 APPLE ROBERT F M X D 1.65 3,000 893,002
2017-04-04 4 APPLE ROBERT F S X D 3.0019 -37,000 890,002 2,671,697
2017-04-04 4 APPLE ROBERT F M X D 1.65 37,000 927,002
2017-04-04 4 JACOB LEONARD S S X D 2.9001 -21,762 218,885 634,788
2017-04-04 4 JACOB LEONARD S M X D 1.65 21,762 240,647
2017-04-03 4 JACOB LEONARD S S X D 2.8785 -20,000 218,885 630,060
2017-04-03 4 JACOB LEONARD S M X D 1.65 20,000 238,885
2017-03-31 4 GARRITY THOMAS J S X D 2.9092 -30,000 160,213 466,092
2017-03-31 4 GARRITY THOMAS J M X D 1.65 30,000 190,213
2017-03-31 4 GONELLA JACQUES M D 1.65 30,000 12,056,413
2016-12-30 4 GONELLA JACQUES J D 2,900,000 12,026,413
2017-12-27 4 APPLE ROBERT F F D 2.35 -39,717 890,002
2017-12-27 4 APPLE ROBERT F M D 1.23 60,000 929,719
2016-12-09 4 Powell Fred M P D 2.025 100,000 100,000 202,500
2016-12-01 4 JACOB LEONARD S S D 1.9708 -20,000 218,885 431,379
2016-12-01 4 JACOB LEONARD S M D 1.23 20,000 238,885
2016-06-30 4 APPLE ROBERT F A D 1.05 11,223 869,719
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
ATRS : Antares Pharma Stock Analysis and Research Report

2017-10-31 - Asif

Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Antares Pharma, Excellent Risk-Reward Profile

6h seekingalpha
Company remains a viable acquisition candidate, especially in the likely aftermath of Xyosted being approved by the FDA. (68-0)

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

8h seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far. (688-3)

Institutional Top Ideas Series: Opaleye Management

2018-05-17 seekingalpha
Their top two holdings are heavily weighted and they are capitalizing on the targeted oncology theme as well. (113-1)

Antares Pharma Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-08 seekingalpha
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q1 earnings call. (34-0)

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

2018-05-07 seekingalpha
The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire. (603-2)